Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) posted its earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.12, Zacks reports.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.40 on Wednesday. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.44. The company has a market cap of $101.00 million, a PE ratio of -0.68 and a beta of 1.87. The stock’s 50 day simple moving average is $1.54 and its 200-day simple moving average is $1.45.

Analyst Upgrades and Downgrades

ZNTL has been the subject of a number of analyst reports. HC Wainwright raised Zentalis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 7th. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company cut their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $5.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in Zentalis Pharmaceuticals by 177.6% during the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after purchasing an additional 396,233 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after buying an additional 2,111,951 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the second quarter worth about $37,000. Sei Investments Co. boosted its position in Zentalis Pharmaceuticals by 373.1% during the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock worth $194,000 after acquiring an additional 131,780 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock valued at $770,000 after acquiring an additional 515,257 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.